Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NIZAR M TANNIR and SURENA MATIN.
NIZAR M TANNIR
Connection Strength
3.573
SURENA MATIN
  1. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710.
    View in: PubMed
    Score: 0.457
  2. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
    View in: PubMed
    Score: 0.189
  3. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.147
  4. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.134
  5. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005.
    View in: PubMed
    Score: 0.111
  6. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7.
    View in: PubMed
    Score: 0.110
  7. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
    View in: PubMed
    Score: 0.106
  8. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011 Dec; 22(12):2661-2666.
    View in: PubMed
    Score: 0.102
  9. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol. 2011 May; 22(5):1243.
    View in: PubMed
    Score: 0.098
  10. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44.
    View in: PubMed
    Score: 0.095
  11. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011 May; 22(5):1048-1053.
    View in: PubMed
    Score: 0.095
  12. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7.
    View in: PubMed
    Score: 0.094
  13. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81.
    View in: PubMed
    Score: 0.086
  14. MR-Linac-guided stereotactic radiotherapy for CT-indiscernible intravascular renal cell carcinoma tumours. BJUI Compass. 2024 Oct; 5(10):913-915.
    View in: PubMed
    Score: 0.061
  15. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
    View in: PubMed
    Score: 0.060
  16. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.058
  17. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684.
    View in: PubMed
    Score: 0.056
  18. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
    View in: PubMed
    Score: 0.051
  19. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17.
    View in: PubMed
    Score: 0.050
  20. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620.
    View in: PubMed
    Score: 0.050
  21. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23.
    View in: PubMed
    Score: 0.050
  22. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753.
    View in: PubMed
    Score: 0.047
  23. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960.
    View in: PubMed
    Score: 0.046
  24. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
    View in: PubMed
    Score: 0.043
  25. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496.
    View in: PubMed
    Score: 0.041
  26. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757.
    View in: PubMed
    Score: 0.040
  27. Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma. Carcinogenesis. 2017 10 26; 38(11):1129-1135.
    View in: PubMed
    Score: 0.038
  28. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res. 2017 10 01; 77(19):5313-5326.
    View in: PubMed
    Score: 0.038
  29. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627.
    View in: PubMed
    Score: 0.037
  30. Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliat Support Care. 2018 04; 16(2):146-154.
    View in: PubMed
    Score: 0.037
  31. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.036
  32. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.036
  33. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer. 2017 01 03; 116(1):77-84.
    View in: PubMed
    Score: 0.036
  34. Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psychooncology. 2017 09; 26(9):1361-1368.
    View in: PubMed
    Score: 0.035
  35. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.034
  36. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.034
  37. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82.
    View in: PubMed
    Score: 0.034
  38. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15.
    View in: PubMed
    Score: 0.033
  39. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 05; 35(21):2687-97.
    View in: PubMed
    Score: 0.033
  40. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.033
  41. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.032
  42. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.032
  43. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22.
    View in: PubMed
    Score: 0.032
  44. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psychooncology. 2015 Nov; 24(11):1477-84.
    View in: PubMed
    Score: 0.032
  45. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.032
  46. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol. 2015 Jun; 67(2):149-56.
    View in: PubMed
    Score: 0.032
  47. Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma. Carcinogenesis. 2015 Feb; 36(2):249-55.
    View in: PubMed
    Score: 0.031
  48. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42.
    View in: PubMed
    Score: 0.030
  49. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol. 2014 Mar 01; 32(7):663-70.
    View in: PubMed
    Score: 0.030
  50. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. 2012 Dec; 110(11):1742-6.
    View in: PubMed
    Score: 0.026
  51. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011 Dec; 60(6):1273-9.
    View in: PubMed
    Score: 0.025
  52. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol. 2011 Jan; 42(1):146-50.
    View in: PubMed
    Score: 0.024
  53. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol. 2011 Jan; 59(1):10-5.
    View in: PubMed
    Score: 0.024
  54. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol. 2010 Nov; 184(5):1877-81.
    View in: PubMed
    Score: 0.023
  55. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010 Jul 15; 116(14):3378-88.
    View in: PubMed
    Score: 0.023
  56. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009 Nov 15; 125(10):2342-8.
    View in: PubMed
    Score: 0.022
  57. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7.
    View in: PubMed
    Score: 0.021
  58. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):801-7.
    View in: PubMed
    Score: 0.021
  59. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41.
    View in: PubMed
    Score: 0.021
  60. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis. 2008 Nov; 29(11):2112-9.
    View in: PubMed
    Score: 0.020
  61. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008 Jul; 180(1):94-8.
    View in: PubMed
    Score: 0.020
  62. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007 Nov; 178(5):1896-900.
    View in: PubMed
    Score: 0.019
  63. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol. 2007 Oct; 178(4 Pt 1):1492-6.
    View in: PubMed
    Score: 0.019
  64. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol. 2005 May; 16(5):679-88.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.